Non-Small Cell Lung Cancer (NSCLC) is the most common type of lung cancer and can be defined as any type of epithelial lung cancer other than SCLC.
PD-L1 (also known as CD274) is considered an immune checkpoint is facilitating anti-tumour suppression of the immune pathway.
Programmed death-ligand 1 (PD-L1) Non-small Cell Lung Cancer (NSCLC) Epidemiological Segmentation
The Epidemiological Segmentation of Programmed death-ligand 1 (PD-L1) Non-small Cell Lung Cancer (NSCLC) in 7MM from 2017 to 2030 is segmented as:-
- Total Incident Cases of NSCLC
- Total Incident Cases of NSCLC Patients by Histology
- Total Diagnosed Cases of NSCLC Patients by Stages
- Total NSCLC cases of patients by PD-L1
- Total Treated cases of NSCLC patients by Line of Therapies
Programmed death-ligand 1 (PD-L1) Non-small Cell Lung Cancer (NSCLC) Epidemiology
- Total cases of Programmed death-ligand 1 (PD-L1) mutated NSCLC in 7MM in 2017 were 242,014 Programmed death-ligand 1 (PD-L1) NSCLC cases in the United States in 2017 were 89,597
Programmed death-ligand 1 (PD-L1) Non-small Cell Lung Cancer (NSCLC) Market
The market size of Programmed death-ligand 1 (PD-L1) mutated NSCLC in 7MM in 2017 was USD 6,536 million.
Programmed death-ligand 1 (PD-L1) Non-small Cell Lung Cancer (NSCLC) Market Drivers
- Increasing Use of Biomarker Testing
- Increase in the Mutation Specific Trials Activity
- Increasing Incidence of Programmed death-ligand 1 (PD-L1) mutated NSCLC
Programmed death-ligand 1 (PD-L1) Non-small Cell Lung Cancer (NSCLC) Market Barriers
- Cost-Effectiveness of Therapies
- Cost of Therapies
- Burden of Disease
Programmed death-ligand 1 (PD-L1) Non-small Cell Lung Cancer (NSCLC) Emerging Drugs
The Emerging drugs of the Programmed death-ligand 1 (PD-L1) Non-small Cell Lung Cancer (NSCLC) market are
- Canakinumab (ACZ885)
- Avelumab (Bavencio)
- Libtayo (Cemiplimab)
- M7824 (Bintrafusp alfa)
And many others.
Programmed death-ligand 1 (PD-L1) Non-small Cell Lung Cancer (NSCLC) Key Players
The key players in the Programmed death-ligand 1 (PD-L1) Non-small Cell Lung Cancer (NSCLC) market are
- Novartis Pharmaceutical
- Merck KGaA
- Pfizer
- Regeneron Pharmaceuticals
- GlaxoSmithKline
And many others.